144 related articles for article (PubMed ID: 37634280)
21. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Spiegl-Kreinecker S; Pirker C; Filipits M; Lötsch D; Buchroithner J; Pichler J; Silye R; Weis S; Micksche M; Fischer J; Berger W
Neuro Oncol; 2010 Jan; 12(1):28-36. PubMed ID: 20150365
[TBL] [Abstract][Full Text] [Related]
22. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
23. Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.
Ye L; Gu L; Wang Y; Xing H; Li P; Guo X; Wang Y; Ma W
CNS Neurosci Ther; 2024 Mar; 30(3):e14649. PubMed ID: 38448295
[TBL] [Abstract][Full Text] [Related]
24. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
25. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
[TBL] [Abstract][Full Text] [Related]
26. Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo.
Chen TC; Chan N; Minea RO; Hartman H; Hofman FM; Schönthal AH
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30274152
[TBL] [Abstract][Full Text] [Related]
27. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
28. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
29. Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
Feldheim J; Kessler AF; Feldheim JJ; Schulz E; Wend D; Lazaridis L; Kleinschnitz C; Glas M; Ernestus RI; Brandner S; Monoranu CM; Löhr M; Hagemann C
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563629
[TBL] [Abstract][Full Text] [Related]
30. Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)
Kochanowski P; Catapano J; Pudełek M; Wróbel T; Madeja Z; Ryszawy D; Czyż J
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923767
[TBL] [Abstract][Full Text] [Related]
31. Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression.
Zhu Z; Du S; Ding F; Guo S; Ying G; Yan Z
Am J Transl Res; 2016; 8(7):3299-308. PubMed ID: 27508051
[TBL] [Abstract][Full Text] [Related]
32. Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma.
Wang K; Chen D; Qian Z; Cui D; Gao L; Lou M
Cancer Cell Int; 2017; 17():117. PubMed ID: 29225516
[TBL] [Abstract][Full Text] [Related]
33. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
34. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
Yang B; Ma YB; Chu SH
Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
[TBL] [Abstract][Full Text] [Related]
35. A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide.
Chai RC; Chang YZ; Wang QW; Zhang KN; Li JJ; Huang H; Wu F; Liu YQ; Wang YZ
Front Genet; 2019; 10():910. PubMed ID: 31611911
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
37. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
[TBL] [Abstract][Full Text] [Related]
38. Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?
Tini P; Nardone V; Pastina P; Marampon F; Sebaste L; Cerase A; Tombolini V; Pirtoli L; Mazzei MA
Clin Neurol Neurosurg; 2019 Sep; 184():105445. PubMed ID: 31325903
[TBL] [Abstract][Full Text] [Related]
39. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
[TBL] [Abstract][Full Text] [Related]
40. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
